The Scientist - Home

Smarter consumership and rigid demands from investors leave little room for fuzzy thinking in entrepreneurial plans Despite recent setbacks in drug approvals, the mounting campaign for cost-cutting in the health care industry, and ongoing tribulations in the United States and global financial markets, the domestic biotechnology startup world is apparently holding its own. As the industry at large matures, analysts say, new entrants are learning from the highly publicized mistakes of their pr

Five Researchers Receive King Faisal Prizes In Science And Medicine Two From France To Get Wolf Prize In Mathematics Herbert Walther, director of the Max Planck Institute for Quantum Optics in Munich, Germany, and a professor of physics at Munich University, and Steven Chu, chairman of the physics department at Stanford University, have been selected as recipients of the King Faisal International Prize for Science. Jean-Claude Chermann, director of the laboratory of retroviruses and

A recently proposed congressional resolution and statements by President Clinton are giving some scientists and diplomats the feeling that the United States will soon return to UNESCO after a decade of absence. If so, the group would once again be allowed to hire Americans for scientific, teaching, and administrative positions. UNESCO--the United Nations Educational, Scientific, and Cultural Organization--was abandoned by the Reagan administration in December 1983 for what were seen as large

Patently Special To Russia With A Rebuke More Messages For Coloradans New Molecule On The Block Stairway To The Stars Skin Care Two Merck & Co. Inc. researchers have been named cowinners of the Inventor of the Year award, given by Intellectual Property Owners, a Washington, D.C.-based nonprofit association that represents owners of patents, trademarks, copyrights and trade secrets. Gary H. Rasmusson and Glenn F. Reynolds will share the $5,000 award, presented at an April 15 ceremony in Wa

SOME QUESTION UNESCO'S SCIENCE Author: Ron Kaufman Though some of those familiar with the United Nations Educational, Scientific, and Cultural Organization (UNESCO) eagerly support a return to the organization by the United States and Great Britain, others say such a move would have no scientific merit. "By going back we'd only get good will--maybe," says Gregory Newell, the assistant secretary of state for U.S. multilateral policy from 1982 to 1985 and the architect of the U.S

Despite chill winds on Wall Street, investors continue to place bets on fledgling biotechnology companies.

University department chairpersons have been pushing to see dollar support for NIH double in the near future Five billion dollars is not enough, according to a group pushing for the federal government to pump more money into the basic biomedical research funded by the National Institutes of Health. And with Bill Clinton now in the White House, members of the group--the National Caucus of Basic Biomedical Science Chairs-- say they are very optimistic about achieving their goal. Composed of 2

While some experts see virtue in the new president's technology policy, others warn of hidden probems High-technology company executives and association officials, along with leading scientists and others in the United States research and development community, are largely upbeat in their initial responses to President Bill Clinton's economic program and his ambitious effort to redirect U.S. technology policy. At the same time, several science and technology policy-watchers interviewed by Th

Stock market declines have taken their toll on established firms, but startup ventures still attract backing Launching a new biotechnology company calls for a number of key ingredients, as any wide-eyed scientist who has tested the entrepreneurial waters will attest. You need your enlightened concept, of course, and the enduring visionary force that eventually is to hammer your concept into shape as a viable product. You also need the right people--and the proper blend of them--to keep the

At an April 1 meeting in Washington, D.C., the Carnegie Commission on Science, Technology, and Government formally began the process of going out of business. The commission's five-year charter ends June 30. The panel was convened in 1988 under the auspices of the Carnegie Corporation of New York to assess the ways in which policymakers take science and technology issues into account when making decisions. The blue-ribbon panel is cochaired by Nobel laureate Joshua Lederberg, former president

N.Mex., is sponsoring a number of events, beginning next week, to mark the 50th anniversary of the Manhattan Project and the opening of the lab. A series of seminars and panel discussions on the scientific and policy implications of the lab's work is slated for April 12-16, featuring speakers such as former laboratory directors Harold Agnew (1970-80) and Don Kerr (1980- 85); Sens. Jeff Bingaman (D-N.Mex.) and Pete Domenici (R-N.Mex.); and Frank von Hippel, editor of the Bulletin of Atomic Scie

In today's otherwise sluggish biomedical job market, career prospects for these scientists are improving in academia as well as industry Immunology research is riding the crest of a wave, with significant laboratory results proliferating, observers of the field say. "Immunology remains one area in biomedicine that has relatively good prospectives for employment, and one that is likely to continue doing somewhat better than most others," says Robert Rich, a professor of microbiology, immuno